Trial reportEndocrine2026
Randomized Double-blind Placebo-controlled study to evaluate the efficacy of fermented deglycyrrhizinated licorice for treatment of diabetic polyneuropathy.
Trial report in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07148804 (Oral α-Amylase Enzyme Replacement for the Treatment of Diabetic Polyneuropathy), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Oral α-Amylase Enzyme Replacement for the Treatment of Diabetic Polyneuropathy
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the efficacy of α-amylase enzyme prepared from fermented deglycyrrhizinated licorice root extract (FDGL) in treating early-stage diabetic polyneuropathy (DPN).
methodsA double-blind, placebo-controlled randomized trial involving 83 type 1 and II diabetic patients aged 15–65 years with diabetes duration ≤ 5 years, serum amylase < 45 IU/L. Patients were not complaining of clinical diabetic polyneuropathy (DPN), yet they showed demonstrable electrophysiological changes (vibration perception threshold [VPT] > 15 V), low nerve conduction velocity (NCV), and low serum amylase levels. Patients were randomized to receive either FDGL capsules (gp A; 0.5 gm twice daily containing 1250 IU of α-amylase) or a matched placebo (gp B) for 6 months. For comparison, 20 healthy volunteers matched for age, sex, and body constitution were recruited (control gp). Primary outcomes were the changes in motor nerve conduction velocity (MCV) and vibration perception threshold (VPT) from baseline. Secondary outcomes included changes in sensory nerve conduction velocity (SCV), serum amylase levels, and HbA1C. Outcomes were assessed at baseline, after 3, and 6 months. The study was registered on ClinicalTrials.gov (NCT07148804).
resultsA total of 83 diabetic patients were analyzed. Compared to placebo, patients who received FDGL (GpA) demonstrated a significant increase in MCV, SCV, and serum amylase with a reduction in VPT at 3 and 6-month follow-up (p < 0.001 for all outcomes). Compared to the control group, this corresponds to a restoration of 32% and 99% of the neurological deficits of MCV and SCV, respectively. HBA1C remained around the baseline values at the end of the study with no significant difference between the groups.
conclusionOral administration of α-amylase enzyme in FDGL significantly improved nerve conduction and restored serum amylase levels in both type I and II diabetic patients. Further studies are needed to verify its effect on other complications. CLINICAL
trial registrationThis study was registered at ClinicalTrials.gov (NCT07148804).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.